- Home
- ADPT vs FBNC Comparison
ADPT vs FBNC Comparison
Compare ADPT & FBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADPT | FBNC |
|---|---|---|
| Founded | 2009 | 1934 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2019 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ADPT | FBNC |
|---|---|---|
| Price | $14.54 | $58.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $17.78 | ★ $61.25 |
| AVG Volume (30 Days) | ★ 2.0M | 188.4K |
| Earning Date | 04-30-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 1.63% |
| EPS Growth | ★ 63.89 | 45.65 |
| EPS | N/A | ★ 2.68 |
| Revenue | ★ $276,976,000.00 | $67,623,000.00 |
| Revenue This Year | $3.98 | $37.82 |
| Revenue Next Year | $22.72 | $2.30 |
| P/E Ratio | ★ N/A | $22.04 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $6.77 | $36.38 |
| 52 Week High | $20.76 | $62.64 |
Technical Indicators
Market Signals| Indicator | ADPT | FBNC |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 63.67 |
| Support Level | $12.19 | $45.57 |
| Resistance Level | $17.72 | $62.53 |
| Average True Range (ATR) | 0.99 | 1.16 |
| MACD | 0.14 | 0.55 |
| Stochastic Oscillator | 70.42 | 93.76 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.